Investigating the role of a specific signaling pathway in pancreatic tumors.
Official title: Role of the CX3CL1-CX3CR1 signaling axis in IPMN
Funded at Mayo Clinic Rochester · NIH-11046696 · Data updated 2026-11-12
This study is looking at how certain signals in the body might affect the growth of early-stage pancreatic tumors called IPMN, with the hope of finding new ways to track and understand these conditions better for people at risk of pancreatic cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | March 1, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $195,698 |
| NIH project number | 5R21AI178147-02 |
| Project ID | NIH-11046696 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with intraductal papillary mucinous neoplasms (IPMN) or those at high risk for developing pancreatic cancer.
✕Less likely to help
Patients with other types of pancreatic tumors or those without any pancreatic lesions may not benefit from this research.
What this research studies
This research focuses on understanding how the CX3CL1-CX3CR1 signaling axis influences the development of intraductal papillary mucinous neoplasms (IPMN), which are precursors to pancreatic cancer. By utilizing advanced techniques like single-cell RNA sequencing and genetically engineered mouse models, the study aims to identify unique cell populations and their interactions within the tumor microenvironment. The goal is to uncover biological mechanisms that drive the progression of these lesions, potentially leading to new biomarkers for disease monitoring.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for early detection and treatment of pancreatic cancer.
How similar studies have gone: Previous research has shown promising results in understanding tumor microenvironments and signaling pathways in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Ding, Li — Mayo Clinic Rochester
- Study coordinator: Ding, Li
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.